Navigation Links
NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
Date:8/25/2009

g and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases. DAS181 (Fludase((R))), a recombinant fusion protein, inactivates viral receptors on the cells of the human respiratory tract, thereby preventing and treating infection by influenza, including potential pandemic strains, and by parainfluenza viruses (which may cause serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic). Unlike current antiviral compounds and vaccines, DAS181 targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with currently-available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance. Viradin((TM)), invented and developed by NexBio, is a parenteral protein under development, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fevers and bacterial biothreat sepsis. TOSAP((TM)) is a technology invented and developed by NexBio and is used to formulate DAS181 for inhalation, as well as to make nano/microparticles from virtually any type of molecule. TOSAP((TM)) is offered for the formulation of compounds of partners, under license.

For more information about NexBio, Inc., please visit http://www.nexbio.com

    Contact:

    David Wurtman, M.D., M.B.A
    VP, Corporate Development
    10665 Sorrento Valley Road
    San Diego, CA  92121
    Phone: (858) 452-2631
    dwurtman@nexbio.com

* FDA has yet to approve the name Fludase.

DISCLOSURE NOTICE:

This release contains forward-looking information about the research and development program of
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. Abbott HIV Test Demonstrates Earlier Disease Detection
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
5. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
6. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
7. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
8. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
9. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
10. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
11. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015 Veracyte, ... preliminary data demonstrating the ability of the company,s ... (IPF) from other interstitial lung diseases (ILDs) using ... classifier,s potential to help thousands of patients avoid ... in IPF diagnosis – a frequent challenge for ...
(Date:5/20/2015)... , May 20, 2015  Select Medical Corporation ... Federal Trade Commission granted early termination of the ... Act of 1976, as amended, applicable to the ... Corporation, a joint venture that Select has created ... As previously announced, MJ Acquisition Corporation has ...
(Date:5/20/2015)... 20, 2015  Marc Tessier-Lavigne, president of The ... $100 million from The Marie-Josée and Henry R. ... building that will be the centerpiece of the ... Henry R. Kravis Research Building, two stories high, ... approximately three city blocks following the shoreline of ...
(Date:5/20/2015)... May 19, 2015 Research and Markets ... of the "Bone Morphogenetic Proteins Market (Types ... Reconstructive and Oral - Maxillofacial) - Global Industry ... - 2022" report to their offering. ... studied based on the types of recombinant BMPs, ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... Sciences Holdings, Inc. (OTC Bulletin Board: ... development and commercialization of novel drugs in the therapeutic ... that it has submitted a full proposal to the ... BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense .  It ...
... imaging system, scientists have tracked a group of near-infrared ... the body and out again, providing a description of ... could be used in developing therapeutic agents to treat ... of the health effects of air pollution. ...
... 2010 Financial Results ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Scientist chronicle nanoparticles' journey from the lungs into the body 2Scientist chronicle nanoparticles' journey from the lungs into the body 3Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3Oncothyreon Reports Third Quarter 2010 Financial Results 4Oncothyreon Reports Third Quarter 2010 Financial Results 5Oncothyreon Reports Third Quarter 2010 Financial Results 6Oncothyreon Reports Third Quarter 2010 Financial Results 7Oncothyreon Reports Third Quarter 2010 Financial Results 8Oncothyreon Reports Third Quarter 2010 Financial Results 9Oncothyreon Reports Third Quarter 2010 Financial Results 10Oncothyreon Reports Third Quarter 2010 Financial Results 11
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... with injury better than others. A flesh wound or muscle ... will heal. The prognosis for a heart attack, on the ... been thought that cardiac cells (cardiomyocytes) lack the capacity for ... from a heart attack. However, recent evidence suggests that the ...
... Therapeutics, today announced the grant of a major patent, ... Trademark Office on microarray products allowing the specific detection ... for the discovery of alternative RNA splicing events. The ... of five oligonucleotides for the detection of each splice ...
... results in irreversible damage to the heart that ... results from the limited ability of the myocardium ... from Tufts University now document the existence of ... stem cells with therapeutic potency for myocardial tissue ...
Cached Biology News:Heart repair gets new muscle 2Products containing specific probes for detecting alternative splice forms protected 2
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
... isomers are predominantly used for labeling proteins, ... labeling peptides and nucleotides because they give ... often required in the conjugation processes. 5-TAMRA ... labeling peptides and proteins. 6-TAMRA is predominately ...
Biology Products: